Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $640
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst David Phung has maintained an Overweight rating on Eli Lilly (NYSE:LLY) and raised the price target from $617 to $640.
September 05, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Eli Lilly and raised the price target from $617 to $640, which could positively impact the stock.
The raised price target by Morgan Stanley indicates a positive outlook for Eli Lilly. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100